The novel anthracycline annamycin is not affected by P-glycoprotein- related multidrug resistance: Comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines

Blood

Volumn 88, Issue 2, 1996, Pages 633-644

  Consoli, Ugo ^b   Priebe, Waldemar ^b   Ling, Yi He ^b   Mahadevia, Radha ^b   Griffin, Mark ^b   Zhao, Shourong ^b   Perez Soler, Roman ^b   Andreeff, Michael ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANNAMYCIN; DOXORUBICIN; GLYCOPROTEIN P; IDARUBICIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG EFFICACY; HUMAN; HUMAN CELL; LEUKEMIA; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

EID: 0030013639     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.2.633.bloodjournal882633     Document Type: Article

References (52)

1. Sanford MS, Melvin S: Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA 91:3497, 1994
2. Maslak P, Hegewisch-Becker S, Godfrey L, Andreeff M: Flow cytometric determination of the multidrug-resistant phenotype in acute leukemia. Cytometry 17:84, 1994
3. Biedler JL, Riehm H: Cellular resistance to actinomycin D in Chinese hamster cells in vitro: Cross resistance, radioautographic and cytogenetic studies. Cancer Res 30:1174, 1970
4. Juliano RL, Ling V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 445:152, 1976
5. Bradley G, Juranka P, Ling V: Mechanism of multidrug resistance. Biochim Biophys Acta 948:87, 1988
6. Hardy SP, Goodfellow HR, Valverde MA, Gill DR, Sepulveda FV, Higgins CF: Protein kinase C-mediated phosphorylation of the human multidrug resistance P-glycoprotein regulates cell volume-activated chloride channels. EMBO J 14:68, 1995
7. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB: Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47:381, 1987
8. Ueda K, Cadarelli C, Gottesman MM, Pastan I: Expression of full length c-DNA for the human "mdr 1" gene confers resistance to colchicine, doxorubicin and vinblastine. Proc Natl Acad Sci USA 84:3004, 1987
9. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y: Increased accumulation of vincristine and adriamycin in drug resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 42:4730, 1982
10. Moscow JA, Morrow CS, Cowan KH: Multidrug resistance, in Pinedo HM, Longo DL, Chabner BA (eds): Cancer Chemotherapy and Biological Response Modifiers. New York, NY, Elsevier Science, 1992, p 91
11. Friche E, Skosgaard T, Nissen NI: Effect of verapamil on daunorobicin accumulation in Ehrlich ascites tumor cells. Cancer Chemother Pharmacol 19:35, 1987
12. Formelli F, Cleris L, Carsana R: Effect of verapamil on doxorubicin activity and pharmacokinetics in mice bearing resistant and sensitive tumors. Cancer Chemother Pharmacol 21:329, 1988
13. Kaye SB: Reversal of multidrug resistance. Cancer Treat Rev 17:37, 1990
14. Willingham MC, Cornwell MM, Cadarelli C, Gottesman MM, Pastan I: Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive KB cells: Effect of verapamil and other drugs. Cancer Res 46:5941, 1986
15. Stewart DJ, Evans WK: Non-chemotherapeutic agents that potentiate chemotherapy efficacy. Cancer Treat Rev 16:1, 1989
16. Durie BMG, Dalton WS: Reversal of drug resistance in multiple myeloma with verapamil. Br J Haematol 68:203, 1988
17. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE: P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9:17, 1991
18. Yahanda AM, Adler KM, Fisher GA, Brophy NA: Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 10:1624, 1992
19. Cersosimo RJ: Idarubicin: An anthracycline antineoplastic agent. Clin Pharmacy 11:152, 1992
20. Casazza AM: Experimental evaluation of anthracycline analogues. Cancer Treat Rep 63:835, 1979
21. Berman E, McBride M: Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 79:3267, 1992
22. Michieli M, Michelutti A, Damiani D, Pipan C, Raspadori D, Lauria F, Baccarani M: A comparative analysis of the sensitivity of multidrug resistant (MDR) and non-MDR cells to different anthracycline derivatives. Leuk Lymphoma 9:255, 1993
23. Michieli M, Damiani D, Michelutti A, Melli C, Russo D, Fanin R, Baccarani M: p170-dependent multidrug resistance. Restoring full sensitivity to idarubicin with verapamil and cyclosporin A derivatives. Haematologica 79:119, 1994
24. Berman E, Heller G, Santorsa J, McKenzie S, Gee TS, Kempin S, Gulati S, Andreeff M, Kolitz J, Gabrilove J, Reich L, Mayer K, Keefe D, Trainor K, Schluger A, Penenberg D, Raymond V, O'Reilly R, Jhanwar S, Young C, Clarkson B: Result of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 77:1666, 1991
25. Rotoli B, for the Gimema Cooperative Group: Idarubicin as first line treatment for adult (age 55-80) AML. Conclusive results of a Gimema randomized trial. Haematologica 76:8, 1991
26. Wiernik PH, Banks PCL, Case DC, Arlin ZA, Periman PO, Todd MB, Ritch PS, Enck RE, Weitberg AB: Cytarabine plus idarubicin or daunorubicin as induction therapy and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 79:313, 1992
27. Priebe W, Perez-Soler R: Design and tumor targeting of anthracyclines able to overcome multidrug resistance: A double-advantage approach. Pharmac Ther 60:215, 1993
28. Priebe W, Van NT, Burke TG, Perez-Soler R: Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity. Anticancer Drugs 4:37, 1993
29. Pearce HL, Winter MA, Beck WT: Structural characteristics of compounds that modulate P-glycoprotein-associated multidrug resistance. Adv Enzyme Regul 30:357, 1990
30. Goormaghtigh E, Chatelain P, Caspers J, Ruysschaert JM: Evidence of complex between adriamycin derivatives and cardiolipin: Possible role in cardiotoxicity. Biochem Pharmacol 29:3003, 1980
31. Goormaghtigh E, Chatelain P, Caspers J, Ruysschaert JM: Evidence of specific complex between adriamycin and negatively charged phospholipids. Biochim Biophys Acta 597:1, 1980
32. Ling YH, Zou Y, Priebe W, Perez-Soler R: Partial overcoming of multidrug resistance by annamycin is associated with similar inhibition of DNA synthesis in the nuclear matrix of sensitive and resistant cells. Int J Cancer 61:402, 1995
33. Ling YH, Priebe W, Yang LY, Burke TG, Pommier Y, Perez-Soler R: In vitro cytotoxicity, cellular pharmacology, and DNA lesions induced by annamycin, an anthracycline derivative with high affinity for lipid membranes. Cancer Res 53:1583, 1993
34. Perez-Soler R, Priebe W: Anthracycline antibiotics with high liposome entrapment: structural features and biological activity. Cancer Res 50:4260, 1990
35. Zou Y, Ling YH, Van NT, Priebe W, Perez-Soler R: Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties. Cancer Res 54:1479, 1994
36. Ling YH, Priebe W, Perez-Soler R: Apoptosis induced by anthracycline antibiotic in p388 parent and multidrug resistant cells. Cancer Res 53:1845, 1993
37. Horton D, Priebe W: 4-Demethoxy-3′-desamino-2′-halo anthracycline and pharmaceutical composition containing same. US patent 4 537 882, August 27 1985
38. Chomcyznsky P, Sacchi N: Single-step method of RNA isolation by acid guanidium isothiocyanate-phenol-chloroform extraction. Anal Biochem 102:156, 1987
39. Drach D, Zhao S, Drach J, Mahadevia R, Gattringer C, Huber H, Andreeff M: Subpopulation of normal peripheral blood and bone marrow cells express a functional multidrug resistance phenotype. Blood 80:2729, 1992
40. Egorin MJ, Hildebrand RC, Cimino EF, Bauchur NR: Cytofluorescence localization of adriamycin and daunorubicin. Cancer Res 34:2243, 1974
41. Krishan A, Ganapathi R: Laser flow cytometry and cancer chemotherapy: Detection of intracellular anthracyclines by flow cytometry. J Histochem Cytochem 27:1655, 1979
42. de Lange JHM, Schipper NW, Schuurhuis GJ, ten Kate TK, van Heijningen THM, Pinedo HM, Lankelma J, Baak JPA: Quantitation by laser scan microscopy of intracellular doxorubicin distribution. Cytometry 13:571, 1992
43. Durand RE, Olive PL: Flow cytometry studies of intracellular adriamycin in single cells in vitro. Cancer Res 41:3489, 1981
44. McGown AT, Ward TH, Fox BW: Comparative studies of the uptake of daunorubicin in sensitive and resistant P388 cell lines by flow cytometry and biochemical extraction procedures. Cancer Chemother Pharmacol 11:113, 1983
45. Luk CK, Tannock IF: Flow cytometry analysis of doxorubicin accumulation in cells from human and rodent cell lines. J Natl Cancer Institute 1:55, 1989
46. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV, Deeley RG: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650, 1992
47. r 110,000 vesicular protein in non-p-glycoprotein-mediated multidrug resistance. Cancer Res 53:1475, 1993
48. Zhao S, El-Tounsi I, Lin Y, Andreeff M: Increased expression of bcl-2 family gene in HL-60 doxorubicin resistant cell line and acute myeloid leukemia cells treated with chemotherapy. Blood 86:2063, 1995 (abstr, suppl 1)
49. Perez-Soler R, Ling YH, Zou Y, Priebe W: Cellular pharmacology of the potentially non-cross-resistant anthracycline annamycin entrapped in liposomes in KB and KB-Vl cells. Cancer Chemother Pharmacol 34:109, 1994
50. Marie JP, Zittoun R, Sikic BJ: Multidrug resistance (mdr-1) gene expression in adult acute leukemias: correlation with treatment outcome and in vitro drug sensitivity. Blood 78:586, 1991
51. Sanfilippo O, Ronchi E, De Marco E, Di Fronzio G, Silvestrini R: Expression of P-glycoprotein in breast cancer tissue and in vitro resistance to doxorubicin and vincristine. Br J Cancer 27:155, 1991
52. Grandi M, Pezzoni G, Ballinari D, Capolongo L, Suarato A, Bargiotti A, Faiardi D, Spreafico F: Novel anthracyclin analogs. Cancer Treat Rev 17:133, 1990